#FDA approval

The Food and Drug Administration may approve the next site-agnostic treatment in August.

First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.

Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.

Eighty percent of medications that receive accelerated approval don’t extend overall survival.

Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.

Piqray plus Faslodex prolonged progression-free survival for metastatic breast cancer patients with PIK3CA gene mutation.

FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.

There are now five targeted therapies for the most common type of liver cancer.

Study found Venclexta plus Gazyva (obinutuzumab) delayed disease progression in previously untreated patients.

Antibody-drug combination reduced the risk of recurrence after surgery by half compared with Herceptin.

Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.

Balversa led to tumor regression in about a third of patients with susceptible genetic mutations.

Ibrance appears safe and effective for men in real-world use.

Progression-free and overall survival improved in patients treated with Tecentriq plus chemotherapy.

Cabometyx is the third liver cancer drug approved in the past six months.